EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial

Da Hea Seo, Kyung Wan Min, Ho Sang Sohn, Sang Yong Kim, In-Kyung Jeong iD, Cheol-Young Park iD, Kun-Ho Yoon iD, So Hun Kim iD, Bong-Soo Cha iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70257 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Da Hea Seo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha University College of Medicine, Incheon, Republic of Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Metformin, Benzhydryl Compounds, Glucosides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chong Kun Dang Pharmaceutical Corp., Seoul, Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This study aimed to evaluate the efficacy and safety of triple therapy with lobeglitazone 0.5 mg as an add‐on treatment compared with placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin. Materials and Methods In this Phase 3, multicentre, double‐blind, randomised trial, patients with T2DM who had an insufficient response to metformin (≥1000 mg/day) and empagliflozin 10 mg/day (Study 1) or 25 mg/day (Study 2) were randomised to receive either lobeglitazone 0.5 mg/day, or placebo once daily for 24 weeks. Participants then entered an open‐label extension phase for an additional 28 weeks, bringing the total treatment duration to 52 weeks. The primary endpoint was the change from baseline in glycated haemoglobin ( HbA1c ) at 24 weeks.

Results

At 24 weeks, the mean change in HbA1c was significantly greater with lobeglitazone than with placebo, regardless of the background empagliflozin dose (−0.71%; 95% confidence interval, −0.88 to −0.55; p < 0.001 in Study 1 and −0.62%; −0.79 to −0.45; p < 0.001 in Study 2). A higher proportion of patients achieved HbA1c levels

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2MetforminBenzhydryl CompoundsGlucosidesHypoglycemic AgentsThiazolidinedionesPyrimidinesHumansDouble-Blind MethodMaleFemaleDrug Therapy, CombinationMiddle AgedGlycated HemoglobinAgedBlood GlucoseTreatment OutcomeGlycemic ControlAdult

Stichwörter der Autor:innen

SGLT2 inhibitorclinical trialmetforminthiazolidinedionestype 2 diabetes

Substanzen

MetforminempagliflozinBenzhydryl CompoundsGlucosidesHypoglycemic AgentsGlycated HemoglobinlobeglitazoneBlood GlucoseThiazolidinedioneshemoglobin A1c protein, human

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha University College of Medicine, Incheon, Republic of Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Eulji General Hospital, Eulji University School of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Republic of Korea.
  • Department of Endocrinology and Metabolism, Chosun University Hospital, Chosun University School of Medicine, Gwangju, Republic of Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea.
  • Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

ORCID-Profile: In-Kyung Jeong, Cheol-Young Park, Kun-Ho Yoon, So Hun Kim, Bong-Soo Cha

Förderung

  • Chong Kun Dang Pharmaceutical Corp., Seoul, Republic of Korea

Zitieren

APA

Seo, D. H., Min, K. W., Sohn, H. S., Kim, S. Y., Jeong, I. K., Park, C. Y., Yoon, K. H., Kim, S. H., & Cha, B. S. (2026). Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70257

Vancouver

Seo DH, Min KW, Sohn HS, Kim SY, Jeong IK, Park CY, et al. Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70257

BibTeX
@article{Seo2026,
  author = {Seo, Da Hea and Min, Kyung Wan and Sohn, Ho Sang and Kim, Sang Yong and Jeong, In-Kyung and Park, Cheol-Young and Yoon, Kun-Ho and Kim, So Hun and Cha, Bong-Soo},
  title = {Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70257}
}
Kostenlos starten →